Showing 3,181 - 3,200 results of 18,566 for search 'significantly ((((((we decrease) OR (linear decrease))) OR (a decrease))) OR (mean decrease))', query time: 0.41s Refine Results
  1. 3181
  2. 3182

    Primary antibodies used for immunoblot analysis. by Iratxe Zuazo-Gaztelu (21071939)

    Published 2025
    “…IRE1 silencing led to activation of TP53 and CDKN1A/p21 in conjunction with increased DNA damage and chromosome instability, while decreasing heterochromatin as well as DNA and histone H3K9me3 methylation. …”
  3. 3183
  4. 3184
  5. 3185

    The hourly temperatures in the phytotron. by Lifeng Guo (17320116)

    Published 2025
    “…After 10 days of exposure to LTS, the pollen viability decreased most significantly at the heading stage by 44.67%, followed by the booting and the tillering stages. …”
  6. 3186

    Fuchioka dataset 251021. by Yusuke Fuchioka (22806178)

    Published 2025
    “…Recent advances in 3D-MRI analysis have enabled quantitative cartilage thickness measurement. We hypothesized that OWHTO would result in measurable decreases in the PF joint cartilage thickness, predominantly medially and detectable using quantitative 3D-MRI. …”
  7. 3187
  8. 3188

    (a to g) Administration of vitamin D3 increased serum phosphorus and triglycerides. by Vidya G. Bettada (22208808)

    Published 2025
    “…Analyses of serum cholesterol, HDL and triglycerides also showed a non-significant decrease in the serum HDL level upon treatment with 125 µg/Kg vitamin D3, but a noticeable increase in the serum triglyceride level was observed with 125 µg/Kg of vitamin D3.…”
  9. 3189

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay by Di Han (618795)

    Published 2025
    “…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
  10. 3190

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay by Di Han (618795)

    Published 2025
    “…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
  11. 3191

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay by Di Han (618795)

    Published 2025
    “…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
  12. 3192

    Functional Delivery Systems for Targeting Tumor Heterogeneity: Reversing Immunosuppression and Modulating Cancer-Immune Interplay by Di Han (618795)

    Published 2025
    “…By developing a delivery vector that specifically targets circulating malignant cells (CMCs) in patient blood samples, we established an ex vivo platform to study the dynamic interplay between patient-derived cancer cells and immune cells. …”
  13. 3193

    Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

    Published 2025
    “…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
  14. 3194

    Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

    Published 2025
    “…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
  15. 3195

    Development and Use of a Galectin-1-Specific Nanobody for Tumor Imaging and Elucidating the Role of Galectin‑1 in Cancer by Philippine Granger Joly de Boissel (21688159)

    Published 2025
    “…Galectin-1 (GAL-1) plays a crucial role in cancer biology, especially in triple-negative breast cancer (TNBC), where it facilitates immune evasion and tumor progression. …”
  16. 3196

    Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

    Published 2025
    “…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
  17. 3197

    Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

    Published 2025
    “…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
  18. 3198

    Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

    Published 2025
    “…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
  19. 3199

    Hydrate-Based Gas Storage Made Greener: Methane Hydrate Formation Enhancement with a Low-Toxicity Promoter by Katipot Inkong (7979942)

    Published 2025
    “…Additionally, the effect of pressure variations (from 8 to 4 MPa at 288.2 K) was analyzed, revealing that a lower pressure decreases both the gas uptake and formation kinetics due to a reduced driving force. …”
  20. 3200